Qiagen (NYSE:QGEN) Analysts Give 'Moderate Buy' Rating

Shares of Qiagen (NYSE:QGEN) have received an average recommendation of "Moderate Buy" from nine research firms monitoring the company, as reported by Marketbeat Ratings. Among these analysts, four have rated the stock as a hold, while five have designated it as a buy. Additionally, the average target price for Qiagen's stock over the next 12 months is $50.07, based on broker reports issued in the past year.

Analyst Ratings and Targets

Qiagen has attracted attention from various investment analysts recently. Jefferies Financial Group reasserted a "buy" rating for Qiagen and updated its price target to $52.50, up from a previous target of $40.83, in a report dated December 10. On January 6, Morgan Stanley maintained an "equal weight" rating but revised its price target down to $46.67 from $48.61. HSBC Global Research changed its stance on Qiagen, elevating it to a "hold" rating on October 17 after previously having a buy rating. In the same vein, HSBC lowered its price target for the company to $47.64.

Institutional Trading Activity

Recent trading activity indicates a notable interest in Qiagen by institutional investors. For instance, GAMMA Investing LLC increased its stake in Qiagen by an impressive 806.5% in the third quarter, acquiring an additional 500 shares to reach a total of 562 shares valued at $26,000. Similarly, MassMutual Trust Co. FSB ADV raised its position in Qiagen shares by 39.8%, now holding 853 shares worth $39,000 after a purchase of 243 additional shares in the third quarter. Furthermore, Geneos Wealth Management Inc. boosted its holdings in Qiagen by 41.5%, amassing 856 shares valued at $38,000, following the acquisition of an extra 251 shares. Other notable institutional purchases include a new stake acquired by Wilmington Savings Fund Society FSB worth $53,000 and an 83.5% increase in holdings by MassMutual Private Wealth & Trust FSB, now owning 1,565 shares worth $70,000. Currently, about 70% of Qiagen's stock is owned by institutional investors.

Current Stock Performance

The trading activities on Qiagen's stock revealed a slight uptick of 0.3% on Monday, with shares opening at $44.66. The company's financial ratios include a current ratio of 2.17, a quick ratio of 1.89, and a debt-to-equity ratio of 0.39. Over the past year, Qiagen has seen a low of $40.15 and a high of $49.30. Furthermore, the company’s 50-day moving average stands at $43.72, while its 200-day moving average is at $43.21. Qiagen's market capitalization is approximately $9.91 billion, and it has a price-to-earnings ratio (P/E) of 111.32, with a P/E/G ratio of 3.03 and a beta of 0.37.

About Qiagen

QIAGEN NV is a holding company that specializes in offering Sample to Insight solutions. Its technology allows customers to extract valuable molecular insights from samples that include DNA, RNA, and proteins sourced from various biological materials, such as blood and tissue.

Qiagen, Stocks, Investment